MariTide is a novel peptide-antibody conjugate designed to treat obesity and T2Ds by activating GLP-1 receptors and blocking GIP receptors. Its dual mechanism and long half-life may enhance durability and help prevent weight regain.
Preclinical studies show greater weight loss with this combined approach than with GLP-1 or GIP targeting alone.
Summary
Amgen’s Phase II trial (NCT05669599) of MariTide (maridebart cafraglutide), a monthly peptide‑antibody conjugate targeting GLP‑1 activation and GIP inhibition, demonstrated strong and ongoing weight loss—including up to ~20% in people with obesity without diabetes and ~17% in those with T2D—alongside car...
